OGI Invests in Start-up Stem Cell Firm for 'Omics Studies | GenomeWeb

NEW YORK (GenomeWeb News) – The Ontario Genomics Institute said today that it has provided funding to Tissue Regeneration Therapeutics (TRT), a company developing umbilical stem cell-based treatments for a range of diseases, that will support 'omics-based research projects.

OGI and the company did not disclose the amount of the investment. The funds will support proteomic and transcriptomic analyses that will provide information the firm will need to gain the regulatory approval to conduct human clinical trials and to differentiate their product from competitors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.